MN1
MN1 (MN1 proto-oncogene, transcriptional regulator) is a nuclear transcriptional activator that controls gene expression during development of the palate and the membranous bones of the skull. It is also known as MGCR1-PEN, MGCR1 and MGCR. Browse Assay Genie's current range of MN1 research reagents below, or read on for the biology behind the target.
MN1 is a transcriptional activator. It specifically regulates expression of TBX22 in the posterior region of the developing palate, and it is required during later stages of palate development for growth and medial fusion of the palatal shelves. In bone, MN1 promotes the maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11, also called RANKL. It is necessary for normal development of the membranous bones of the skull, and it may play a role in tumour suppression.
The MN1 protein is located in the nucleus, consistent with its role in controlling transcription. The mouse ortholog is Mn1, which makes the mouse a relevant system for studying the craniofacial functions described above. Researchers studying this regulator typically work with the MN1 gene, its transcript and the MN1 protein, using tools such as an MN1 antibody to follow its nuclear localisation.
The gene name reflects its history. MN1 was originally designated meningioma (disrupted in balanced translocation) 1, and an earlier name was meningioma chromosome region, hence the aliases MGCR and MGCR1. According to the NCBI Gene summary, the gene contains two sets of CAG repeats and is disrupted by a balanced translocation (4;22) in a meningioma. Its inactivation may contribute to the pathogenesis of meningioma 32.
MN1 regulates TBX22 expression in the posterior developing palate and is required for growth and medial fusion of the palatal shelves.
MN1 is necessary for normal development of the membranous bones of the skull, making it a focus for studies of skull formation.
MN1 promotes maturation and function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL.
The gene is disrupted by a balanced translocation in a meningioma, and MN1 may play a role in tumour suppression.
MN1 is a nuclear transcriptional activator. It regulates TBX22 expression in the posterior developing palate, supports palatal shelf growth and fusion, and promotes calvarial osteoblast maturation, including TNFSF11/RANKL expression. It is necessary for normal development of membranous skull bones and may act in tumour suppression.
The HGNC name is MN1 proto-oncogene, transcriptional regulator, and UniProt lists it as transcriptional activator MN1. Aliases and previous symbols include MGCR1-PEN, MGCR1 and MGCR. Earlier names were meningioma chromosome region and meningioma (disrupted in balanced translocation) 1.
The NCBI Gene summary reports that MN1 is disrupted by a balanced (4;22) translocation in a meningioma, and that its inactivation may contribute to meningioma 32 pathogenesis. UniProt also notes a possible role in tumour suppression. A mouse ortholog, Mn1, exists; check the datasheet of any product for its validated reactivity.
Other transcription-related targets with similar gene symbols that have products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q10571; product specifications from Assay Genie datasheets.